Form 1: Facility reporting form

Adapted from WHO Facility Reporting Form 1

Please submit the completed Facility Reporting Form and any relevant attachments to: MOH\_Biosafety@moh.gov.sg by 18 February 2019

Contents

[Abbreviations and Acronyms 4](#_Toc534358300)

[Declarations 5](#_Toc534358301)

[1. Identification, destruction or retention of WPV/VDPV infectious or potentially infectious material (WPV/VDPV IM or PIM) 6](#_Toc534358302)

[WPV/VDPV infectious material (IM): 6](#_Toc534358303)

[WPV/VDPV potentially infectious material (PIM): 7](#_Toc534358304)

[2. Identification, destruction or retention of OPV/Sabin infectious or potentially infectious material (OPV/Sabin IM or PIM) 8](#_Toc534358305)

[OPV/Sabin infectious material (IM): 8](#_Toc534358306)

[OPV/Sabin potentially infectious material (PIM): 9](#_Toc534358307)

# Abbreviations and Acronyms

CCS GAPIII Containment Certification Scheme

GAPIII Global Action Plan III for Poliovirus Containment

GCC Global Commission for the Certification of the Eradication of Poliomyelitis

IM Infectious material

MoH Ministry of Health

NAC National authority for containment

NCC National Certification Committee for Poliomyelitis Eradication

NPCC National Poliovirus Containment Coordinator

NTFC National Task Force for Containment

OPV Oral polio vaccine

bOPV Bivalent oral polio vaccine (containing Sabin poliovirus type 1 and type 3)

mOPV Monovalent oral polio vaccine (containing one type of Sabin poliovirus)

mOPV1 Monovalent oral polio vaccine type 1

mOPV2 Monovalent oral polio vaccine type 2

mOPV3 Monovalent oral polio vaccine type 3

OPV1 Oral polio vaccine type 1

OPV2 Oral polio vaccine type 2

OPV3 Oral polio vaccine type 3

tOPV Trivalent oral polio vaccine (containing Sabin poliovirus type 1, type 2 and type 3)

PEF Poliovirus-essential facility

PIM Potentially infectious material

PV Poliovirus

PV1 Poliovirus type 1

PV2 Poliovirus type 2

PV3 Poliovirus type 3

VDPV Vaccine-derived poliovirus

VDPV1 Vaccine-derived poliovirus type 1

VDPV2 Vaccine-derived poliovirus type 2

VDPV3 Vaccine-derived poliovirus type 3

WHO World Health Organization

WPV Wild poliovirus

WPV1 Wild poliovirus type 1

WPV2 Wild poliovirus type 2

WPV3 Wild Poliovirus type 3

# Declarations

This reporting form should be used by the facility when reporting the identification, destruction or retention of poliovirus infectious or potentially infectious material (PV IM or PIM) to the Ministry of Health.

Please complete ALL sections of this form.

This form is completed and submitted for:

|  |  |
| --- | --- |
| Name of the facility[[1]](#footnote-1): |       |
| Address: |       |
| Date of submission: |       |

[ ]  I have read and understood the WHO *[Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/)* (PIM Guidance) and I am applying it to provide the information requested in this form.

[ ]  I have completed ALL sections in this form.

Name, designation and affiliation of the person **completing** this form:

|  |  |
| --- | --- |
| Name: |       |
| Designation: |        |
| E-mail: |       |
| Telephone no: |       |
| Signature: |       |
| Date: |       |

Name, designation and affiliation of the person **approving** this report (i.e. Director of the facility):

|  |  |
| --- | --- |
| Name: |       |
| Designation: |        |
| Signature: |       |
| Date: |       |

#

# 1. Identification, destruction or retention of WPV/VDPV infectious or potentially infectious material (WPV/VDPV IM or PIM)

## WPV/VDPV infectious material (IM):

**NOTE**: WPV/VDPV IM include clinical materials from confirmed infections; environmental sewage or water samples that have tested positive for the presence of these viruses; cell culture isolates and reference strains of these viruses; seed stocks and infectious materials from IPV production; infected animals or samples from such animals, including human poliovirus receptor transgenic mice; derivatives produced in the laboratory that have capsid sequences from WPVs, unless demonstrably proven to be safer than Sabin strains; cells persistently infected with poliovirus strains whose capsid sequences are derived from wild poliovirus; as described in the WHO *Global Action Plan to minimize poliovirus facility-associated risk after type-specific eradication of wild polioviruses and sequential cessation of oral polio vaccine use* ([GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/)).

Following [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), I conclude that:

[ ]  The facility **does not** retain any WPV/VDPV **IM,** as follows (please check all that applies):

|  | WPV/VDPV IM | WPV/VDPV IM |
| --- | --- | --- |
|  | Was never possessed(check box if applicable) | Have been destroyed on (please indicate the latest date as dd/mm/yyyy) | Have been inactivated using a method known to inactivate poliovirus on (please indicate the latest date as dd/mm/yyyy) | Have been transferred to a PEF on (please indicate the PEF and the latest date as dd/mm/yyyy) |
| 1. | WPV1/VDPV1 | [ ]  | [ ]        | [ ]        | [ ]        |
| 2. | WPV2/VDPV2 | [ ]  | [ ]        | [ ]        | [ ]        |
| 3. | WPV3/VDPV3 | [ ]  | [ ]        | [ ]        | [ ]        |
| 4. | PV nucleic acid[[2]](#footnote-2) | [ ]  | [ ]        | N/A | N/A |

[ ]  The facility **retains** WPV/VDPV **IM**, as follows:

|  | WPV/VDPV IM | WPV/VDPV IM are retained (please briefly describe the rationale) |
| --- | --- | --- |
| 1. | WPV1/VDPV1 | [ ]        |
| 2. | WPV2/VDPV2 | [ ]        |
| 3. | WPV3/VDPV3 | [ ]        |
| 4. | PV nucleic acid | [ ]        |

## WPV/VDPV potentially infectious material (PIM):

**NOTE:** WPV/VDPV PIM include faecal, respiratory tract, or concentrated sewage samples collected for any purpose in a time and geographic area of WPV/VDPV circulation, identified as PIM following the WHO *Guidance to minimize risks for facilities collecting, handling or storing materials potentially infectious for polioviruses* and its associated *Annex 2* ([PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/)); products of such materials from poliovirus permissive cells or animals; uncharacterized enterovirus-like cell culture isolates from countries known or suspected to have circulating WPV/VDPV at the time of collection; respiratory and enteric stocks handled under conditions where poliovirus contamination or replication is possible; as described in [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/).

Following the [PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), I conclude that:

[ ]  The facility **does not** retain any WPV/VDPV **PIM**, as follows (please check all that applies):

|  | WPV/VDPV PIM | WPV/VDPV PIM |
| --- | --- | --- |
|  | Was never possessed (check box if applicable) | Have been destroyed on (please indicate the latest date as dd/mm/yyyy) | Have been inactivated using a method known to inactivate poliovirus on (please indicate the latest date as dd/mm/yyyy) | Have been transferred to a PEF on (please indicate the PEF and the latest date as dd/mm/yyyy) |
| 1. | WPV1/VDPV1 | [ ]  | [ ]        | [ ]        | [ ]        |
| 2. | WPV2/VDPV2 | [ ]  | [ ]        | [ ]        | [ ]        |
| 3. | WPV3/VDPV3 | [ ]  | [ ]        | [ ]        | [ ]        |
| 4. | PV nucleic acid | [ ]  | [ ]        | N/A | N/A |

[ ]  The facility **retains** WPV/VDPV **PIM**, as follows:

|  | WPV/VDPV PIM | WPV/VDPV PIM are retained (please briefly describe the rationale) |
| --- | --- | --- |
| 1. | WPV1/VDPV1 | [ ]        |
| 2. | WPV2/VDPV2 | [ ]        |
| 3. | WPV3/VDPV3 | [ ]        |
| 4. | PV nucleic acid | [ ]        |

# 2. Identification, destruction or retention of OPV/Sabin infectious or potentially infectious material (OPV/Sabin IM or PIM)

## OPV/Sabin infectious material (IM):

**NOTE:** OPV/Sabin IM include OPV vaccines; cell culture isolates and reference strains of these viruses; seed stocks and infectious materials from OPV or Sabin-IPV production; environmental sewage or water samples that have tested positive for the presence of OPV/Sabin strains; faecal or respiratory secretion samples from recent OPV recipients; infected animals or samples from such animals; derivatives that have capsid sequences from OPV/Sabin strains; cells persistently infected with poliovirus strains whose capsid sequences are derived from OPV/Sabin strains; as described in [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/).

Following [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), I conclude that:

[ ]  The facility **does not** retain any OPV/Sabin **IM**, as follows (please check all that applies):

|  | OPV/Sabin IM | OPV/Sabin IM |
| --- | --- | --- |
|  | Was never possessed (check box if applicable) | Have been destroyed on (please indicate the latest date as dd/mm/yyyy) | Have been inactivated using a method known to inactivate poliovirus on (please indicate the latest date as dd/mm/yyyy | Have been transferred to a PEF on (please indicate the PEF and the latest date as dd/mm/yyyy) |
| 1. | OPV1/Sabin1 | [ ]  | [ ]        | [ ]        | [ ]        |
| 2. | OPV2/Sabin2 | [ ]  | [ ]        | [ ]        | [ ]        |
| 3. | OPV3/Sabin3 | [ ]  | [ ]        | [ ]        | [ ]        |
| 4. | bOPV | [ ]  | [ ]        | [ ]        | [ ]        |
| 5. | tOPV | [ ]  | [ ]        | [ ]        | [ ]        |
| 6. | mOPV1 | [ ]  | [ ]        | [ ]        | [ ]        |
| 7. | mOPV2 | [ ]  | [ ]        | [ ]        | [ ]        |
| 8. | mOPV3 | [ ]  | [ ]        | [ ]        | [ ]        |
| 9. | PV nucleic acid | [ ]  | [ ]        | N/A | N/A |

[ ]  The facility **retains** OPV/Sabin **IM**, as follows:

|  | OPV/Sabin IM | OPV/Sabin IM are retained (please briefly describe the rationale) |
| --- | --- | --- |
| 1. | OPV1/Sabin1 | [ ]        |
| 2. | OPV2/Sabin2 | [ ]        |
| 3. | OPV3/Sabin3 | [ ]        |
| 4. | bOPV | [ ]        |
| 5. | tOPV | [ ]        |
| 6. | mOPV1 | [ ]        |
| 7. | mOPV2 | [ ]        |
| 8. | mOPV3 | [ ]        |
| 9. | PV nucleic acid | [ ]        |

## OPV/Sabin potentially infectious material (PIM):

**NOTE:** OPV/Sabin PIM include faecal, respiratory tract, or concentrated sewage samples collected for any purpose in a time and geographic area of OPV use, identified as PIM following the [PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/); products of such materials from poliovirus permissive cells or animals; respiratory and enteric stocks handled under conditions where OPV/Sabin contamination or replication is possible; as described in [GAPIII](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/).

Following the [PIM Guidance](http://polioeradication.org/polio-today/preparing-for-a-polio-free-world/containment/containment-resources/), I conclude that:

[ ]  The facility **does not** retain OPV/Sabin **PIM**, as follows (please check all that applies):

|  | OPV/Sabin PIM | OPV/Sabin PIM |
| --- | --- | --- |
|  |  | Was never possessed (check box if applicable) | Have been destroyed on (please indicate the latest date as dd/mm/yyyy) | Have been inactivated using a method known to inactivate poliovirus on (please indicate the latest date as dd/mm/yyyy | Have been transferred to a PEF on (please indicate the PEF and the latest date as dd/mm/yyyy) |
| 1. | OPV1/Sabin1 |[ ]  [ ]        | [ ]        | [ ]        |
| 2. |  OPV2/Sabin2 | [ ]  | [ ]        | [ ]        | [ ]        |
| 3. | OPV3/Sabin3 | [ ]  | [ ]        | [ ]        | [ ]        |
| 4. | PV nucleic acid | [ ]  | [ ]        | N/A | N/A |

[ ]  The facility **retains** OPV2/Sabin2 **PIM**, as follows (please check all that applies):

| Type of OPV2/Sabin2 PIM | Procedure used with OPV2/Sabin2 PIM | Risk level | Retention (Please describe the rationale) |
| --- | --- | --- | --- |
| [ ]  Faecal samples  | Inoculation into PV-permissive cells | [ ]  Moderate |       |
| Other laboratory procedures | [ ]  Low |       |
| [ ]  Concentrated sewage | Inoculation into PV-permissive cells | [ ]  Moderate |       |
| Other laboratory procedures | [ ]  Low |       |
| [ ]  Extracted nucleic acid from faecal samples or concentrated sewage | Transfection into PV-permissive cells | [ ]  Moderate |       |
| Other laboratory procedures | [ ]  Lowest |       |
| [ ]  Respiratory tract samples | Inoculation into PV-permissive cells | [ ]  Low |       |
| Other laboratory procedures | [ ]  Lowest |       |
| [ ]  Extracted nucleic acid from respiratory tract samples  | Transfection into PV-permissive cells | [ ]  Low |       |
| Other laboratory procedures | [ ]  Lowest |       |

[ ]  The facility **retains** OPV1/Sabin1 **PIM** or OPV3/Sabin3 **PIM**, as follows (please check all that applies):

| Type of OPV1/Sabin1 PIM or OPV3/Sabin3 PIM | Procedure used with OPV1/Sabin1 PIM or OPV3/Sabin3 PIM | Risk level | Retention(Please describe the rationale) |
| --- | --- | --- | --- |
| [ ]  Faecal samples | Inoculation into PV-permissive cells | [ ]  Moderate |       |
| Other laboratory procedures | [ ]  Low |       |
| [ ]  Concentrated sewage | Inoculation into PV-permissive cells | [ ]  Moderate |       |
| Other laboratory procedures | [ ]  Low |       |
| [ ]  Extracted nucleic acid from faecal samples or concentrated sewage | Transfection into PV-permissive cells | [ ]  Moderate |       |
| Other laboratory procedures | [ ]  Lowest |       |
| [ ]  Respiratory tract samples | Inoculation into PV-permissive cells | [ ]  Low |       |
| Other laboratory procedures | [ ]  Lowest |       |
| [ ]  Extracted nucleic acid from respiratory tract samples  | Transfection into PV-permissive cells | [ ]  Low |       |
| Other laboratory procedures | [ ]  Lowest |       |

1. A facility is defined as any site (e.g. laboratory, repository or vaccine production unit) owned or operated by any level of government, academic institution, corporation, company, partnership, society, association, firm, sole proprietorship or other legal entity [↑](#footnote-ref-1)
2. Poliovirus RNA, cDNA and total nucleic acid extracted from poliovirus infectious materials (e.g., a virus isolate), or synthesized RNA or cDNA (e.g., cDNA clone, synthetic transcript). [↑](#footnote-ref-2)